• Publications
  • Influence
The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
TLDR
68Ga-PSMA-ligand PET/CT can detect recurrent PCa in a high number of patients and can help delay systemic therapy of PCa. Expand
MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis
TLDR
The use of risk assessment with MRI before biopsy and MRI‐targeted biopsy was superior to standard transrectal ultrasonography–guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously. Expand
Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer
TLDR
Among men with nonmetastatic castration‐resistant prostate cancer, metastasis‐free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. Expand
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
TLDR
The biodistribution of the novel 68Ga-PSMA tracer and its ability to detect PC lesions was analysed in 37 patients to suggest that this novel tracer can detect PC relapses and metastases with high contrast. Expand
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
TLDR
68Ga-PSMA PET/CT can detect lesions characteristic for PC with improved contrast when compared to standard 18F-fluoromethylcholine PET/ CT, especially at low PSA levels. Expand
Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience
TLDR
PCa was detected more easily and more accurately with Ga-PSMA PET/MRI than with PET/CT and with lower radiation exposure, Consequently, this new technique could clarify unclear findings onPET/CT. Expand
Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review.
TLDR
Software-based MRI-US fusion targeted biopsy seems to detect more clinically significant cancers deploying fewer cores than standard biopsy, although further high-quality evidence is needed to change current practice. Expand
Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
TLDR
Tissue kinetics of a small molecule inhibitor of PSMA using PET/CT to estimate radiation dosimetry for the potential therapeutic use of 131I-MIP-1095 in men with mCRPC enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions. Expand
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group.
TLDR
Use of the START checklist would improve the quality of reporting in MRI-targeted biopsy studies and facilitate a comparison between standard and MRI- targeted approaches. Expand
Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
TLDR
Compared to systematic, transperineal biopsy as a reference test, magnetic resonance imaging targeted biopsy alone detected as many Gleason score 7 or greater tumors while simultaneously mitigating the detection of lower grade disease. Expand
...
1
2
3
4
5
...